Keith A.A. Fox

119.7k total citations · 25 hit papers
834 papers, 59.8k citations indexed

About

Keith A.A. Fox is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Keith A.A. Fox has authored 834 papers receiving a total of 59.8k indexed citations (citations by other indexed papers that have themselves been cited), including 660 papers in Cardiology and Cardiovascular Medicine, 201 papers in Surgery and 183 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Keith A.A. Fox's work include Acute Myocardial Infarction Research (312 papers), Atrial Fibrillation Management and Outcomes (218 papers) and Antiplatelet Therapy and Cardiovascular Diseases (198 papers). Keith A.A. Fox is often cited by papers focused on Acute Myocardial Infarction Research (312 papers), Atrial Fibrillation Management and Outcomes (218 papers) and Antiplatelet Therapy and Cardiovascular Diseases (198 papers). Keith A.A. Fox collaborates with scholars based in United Kingdom, United States and Canada. Keith A.A. Fox's co-authors include Salim Yusuf, Graeme J. Hankey, Jonathan L. Halperin, Kenneth W. Mahaffey, Manesh R. Patel, Shamir R. Mehta, Daniel E. Singer, Christopher C. Nessel, Jonathan P. Piccini and Richard C. Becker and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Keith A.A. Fox

820 papers receiving 57.1k citations

Hit Papers

Rivaroxaban versus Warfarin in Nonvalvul... 1994 2026 2004 2015 2011 2001 2011 2004 2006 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
    2011 6.6k citations Manesh R. Patel, Kenneth W. Mahaffey et al. New England Journal of Medicine profile →
  2. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
    2001 2.0k citations Shamir R. Mehta, Salim Yusuf et al. The Lancet profile →
  3. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
    2011 1.3k citations Stephen D. Wiviott, Jean‐Pierre Bassand et al. New England Journal of Medicine profile →
  4. A Validated Prediction Model for All Forms of Acute Coronary Syndrome
    2004 1.2k citations Karen S. Pieper, Robert J. Goldberg et al. profile →
  5. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)
    2006 1.1k citations Keith A.A. Fox, Robert J. Goldberg et al. profile →
  6. A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
    1997 1.0k citations Keith A.A. Fox et al. New England Journal of Medicine profile →
  7. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
    2006 981 citations John W. Eikelboom, Shamir R. Mehta et al. Circulation profile →
  8. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes
    2004 971 citations Stephen D. Wiviott, Keith A.A. Fox et al. profile →
  9. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
    2016 942 citations Jonathan L. Halperin, Freek W.A. Verheugt et al. New England Journal of Medicine profile →
  10. Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure
    1998 935 citations Keith A.A. Fox et al. Circulation profile →
  11. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial
    2013 660 citations Anoop Shah, Nicholas L. Mills et al. The Lancet profile →
  12. Vorapaxar in the Secondary Prevention of Atherothrombotic Events
    2012 656 citations David A. Morrow, Eugene Braunwald et al. New England Journal of Medicine profile →
  13. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006
    2007 627 citations Keith A.A. Fox, Philippe Gabríel Steg et al. profile →
  14. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome
    2004 598 citations Keith A.A. Fox, Shamir R. Mehta et al. Circulation profile →
  15. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial
    2002 597 citations Keith A.A. Fox et al. The Lancet profile →
  16. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes
    2009 582 citations Shamir R. Mehta, Christopher B. Granger et al. New England Journal of Medicine profile →
  17. International Day for the Evaluation of Abdominal Obesity (IDEA)
    2007 553 citations Jean‐Pierre Bassand, Keith A.A. Fox et al. Circulation profile →
  18. Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes
    2005 515 citations Shamir R. Mehta, Keith A.A. Fox et al. profile →
  19. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list of the study participants, can be found at www.outcomes.org/grace.
    2002 500 citations Philippe Gabríel Steg, Robert J. Goldberg et al. profile →
  20. Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes
    2010 492 citations Keith A.A. Fox, Salim Yusuf et al. Circulation profile →
  21. Color Doppler Myocardial Imaging: A New Technique for the Assessment of Myocardial function
    1994 481 citations Keith A.A. Fox et al. profile →
  22. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
    2011 440 citations Keith A.A. Fox, Jonathan P. Piccini et al. European Heart Journal profile →
  23. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
    2014 321 citations Jonathan L. Halperin, Graeme J. Hankey et al. Circulation profile →
  24. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study
    2015 304 citations Anoop Shah, David McAllister et al. profile →
  25. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease
    2018 269 citations John W. Eikelboom, Keith A.A. Fox et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith A.A. Fox United Kingdom 109 47.7k 15.5k 12.1k 11.2k 4.8k 834 59.8k
Elliott M. Antman United States 108 49.4k 1.0× 17.3k 1.1× 9.6k 0.8× 11.3k 1.0× 3.9k 0.8× 527 61.0k
Lars Wallentin Sweden 114 49.4k 1.0× 14.3k 0.9× 15.1k 1.2× 7.5k 0.7× 5.6k 1.2× 753 59.3k
Christopher B. Granger United States 119 49.5k 1.0× 13.8k 0.9× 7.3k 0.6× 10.0k 0.9× 5.6k 1.2× 846 63.9k
Harvey D. White New Zealand 99 45.2k 0.9× 21.6k 1.4× 5.8k 0.5× 14.0k 1.3× 3.8k 0.8× 719 57.9k
Carolyn H. McCabe United States 80 29.7k 0.6× 17.3k 1.1× 5.1k 0.4× 9.7k 0.9× 3.0k 0.6× 182 38.6k
Eugene Braunwald United States 104 43.0k 0.9× 20.7k 1.3× 4.5k 0.4× 12.5k 1.1× 4.2k 0.9× 448 59.7k
Sabina A. Murphy United States 97 30.0k 0.6× 17.9k 1.2× 5.8k 0.5× 6.4k 0.6× 3.3k 0.7× 487 43.5k
Frans Van de Werf Belgium 97 29.8k 0.6× 11.9k 0.8× 4.1k 0.3× 9.8k 0.9× 2.6k 0.5× 779 38.8k
Philippe Gabríel Steg France 123 56.5k 1.2× 30.1k 1.9× 9.6k 0.8× 10.3k 0.9× 5.6k 1.2× 1.1k 77.2k
Bernard J. Gersh United States 138 61.8k 1.3× 19.2k 1.2× 5.1k 0.4× 13.7k 1.2× 7.2k 1.5× 1.1k 76.6k

Countries citing papers authored by Keith A.A. Fox

Since Specialization
Citations

This map shows the geographic impact of Keith A.A. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith A.A. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith A.A. Fox more than expected).

Fields of papers citing papers by Keith A.A. Fox

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith A.A. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith A.A. Fox. The network helps show where Keith A.A. Fox may publish in the future.

Co-authorship network of co-authors of Keith A.A. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Keith A.A. Fox. A scholar is included among the top collaborators of Keith A.A. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith A.A. Fox. Keith A.A. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kotanidis, Christos P., Bjørn Bendz, Erlend Sturle Berg, et al.. (2024). Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: individual patient data meta-analysis. European Heart Journal. 45(23). 2052–2062. 30 indexed citations
2.
Bassand, Jean‐Pierre, Saverio Virdone, A. John Camm, et al.. (2023). Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry. Diabetes Obesity and Metabolism. 25(10). 3040–3053. 1 indexed citations
3.
Siegal, Deborah, Frederik H. Verbrugge, Anne‐Céline Martin, et al.. (2023). Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of stroke. Open Heart. 10(2). e002506–e002506.
4.
Haghbayan, Hourmazd, Chris P Gale, Derek P. Chew, et al.. (2021). Clinical risk prediction models for the prognosis and management of acute coronary syndromes. European Heart Journal - Quality of Care and Clinical Outcomes. 7(3). 222–228. 2 indexed citations
5.
Fox, Keith A.A., Saverio Virdone, Karen S. Pieper, et al.. (2021). GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. European Heart Journal - Quality of Care and Clinical Outcomes. 8(2). 214–227. 27 indexed citations
6.
Hung, John, Andreas Roos, David McAllister, et al.. (2020). 23 Performance of the grace 2.0 score in patients with type 1 and type 2 myocardial infarction. A17.1–A17. 1 indexed citations
7.
Dalgaard, Frederik, Karen S. Pieper, Freek W.A. Verheugt, et al.. (2019). GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open. 9(11). e033283–e033283. 22 indexed citations
8.
9.
Magnani, Giulia, Marc P. Bonaca, Eugene Braunwald, et al.. (2015). Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association. 4(3). e001505–e001505. 56 indexed citations
10.
11.
Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, et al.. (2014). Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm. 11(6). 925–932. 55 indexed citations
12.
Diepen, Sean van, Anne S. Hellkamp, Manesh R. Patel, et al.. (2013). Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation Heart Failure. 6(4). 740–747. 83 indexed citations
13.
Morrow, David A., Eugene Braunwald, Marc P. Bonaca, et al.. (2012). Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine. 366(15). 1404–1413. 656 indexed citations breakdown →
14.
Piccini, Jonathan P., Susanna R. Stevens, Yuchiao Chang, et al.. (2012). Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation. 127(2). 224–232. 375 indexed citations
15.
Piccini, Jonathan P., Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2012). Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. Circulation. 126(suppl_21). 6 indexed citations
16.
Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 365(10). 883–891. 6637 indexed citations breakdown →
17.
Eikelboom, John W., Shamir R. Mehta, Keith A.A. Fox, Janice Pogue, & Salim Yusuf. (2008). Abstract 4585: Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial. Circulation. 118. 2 indexed citations
18.
Spencer, Frederick A., Mauro Moscucci, Christopher B. Granger, et al.. (2007). Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. Circulation. 116(24). 2793–2801. 180 indexed citations
19.
Weston, Clive & Keith A.A. Fox. (1991). Pre-Hospital Thrombolysis: Current Status and Future Prospects. Journal of the Royal College of Physicians of London. 25(4). 312–320. 7 indexed citations
20.
Knabb, Robert M., Steven R. Bergmann, Keith A.A. Fox, & Burton E. Sobel. (1987). The temporal pattern of recovery of myocardial perfusion and metabolism delineated by positron emission tomography after coronary thrombolysis.. PubMed. 28(10). 1563–70. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elliott M. Antman Breakdown of academic impact, for papers by Lars Wallentin Breakdown of academic impact, for papers by Christopher B. Granger Breakdown of academic impact, for papers by Harvey D. White Breakdown of academic impact, for papers by Carolyn H. McCabe Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Sabina A. Murphy Breakdown of academic impact, for papers by Frans Van de Werf Breakdown of academic impact, for papers by Philippe Gabríel Steg Breakdown of academic impact, for papers by Bernard J. Gersh
Rankless by CCL
2026